UROwebinar: Standardised PSMA PET Analysis and Reporting Consensus (SPARC) and radio ligand treatment in prostate cancer

 This UROwebinar aims to highlight the elements and rational of the recent Standardised PSMA PET Analysis and Reporting Consensus (SPARC) initiative. This UROwebinar will present the identified SPARC standards alongside example cases to enhance understanding.

 PSMA PET is gaining increasing importance in prostate cancer management. There is a strong need to standardise reading and reporting of PSMA PET to ensure accurate information transfer from nuclear medicine to clinicians.

 PSMA-based radioligand treatment is also gaining importance. This UROwebinar will also cover the current landscape of radioligand treatment and the ideal patient selection for radioligand treatment to facilitate optimal use of this treatment in prostate cancer patients.